CYTOMX THERAPEUTICS INC (CTMX) Fundamental Analysis & Valuation

NASDAQ:CTMX • US23284F1057

Current stock price

4.4 USD
-1.05 (-19.27%)
At close:
4.5 USD
+0.1 (+2.27%)
Pre-Market:

This CTMX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. CTMX Profitability Analysis

1.1 Basic Checks

  • CTMX had negative earnings in the past year.
  • In the past year CTMX has reported a negative cash flow from operations.
  • In the past 5 years CTMX reported 4 times negative net income.
  • In the past 5 years CTMX always reported negative operating cash flow.
CTMX Yearly Net Income VS EBIT VS OCF VS FCFCTMX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 17.70%, CTMX belongs to the top of the industry, outperforming 95.75% of the companies in the same industry.
  • CTMX's Return On Equity of 26.09% is amongst the best of the industry. CTMX outperforms 96.33% of its industry peers.
  • With an excellent Return On Invested Capital value of 15.67%, CTMX belongs to the best of the industry, outperforming 96.14% of the companies in the same industry.
Industry RankSector Rank
ROA 17.7%
ROE 26.09%
ROIC 15.67%
ROA(3y)-3.97%
ROA(5y)-11.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTMX Yearly ROA, ROE, ROICCTMX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K

1.3 Margins

  • CTMX has a Profit Margin of 24.66%. This is amongst the best in the industry. CTMX outperforms 94.21% of its industry peers.
  • With an excellent Operating Margin value of 20.46%, CTMX belongs to the best of the industry, outperforming 93.82% of the companies in the same industry.
Industry RankSector Rank
OM 20.46%
PM (TTM) 24.66%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTMX Yearly Profit, Operating, Gross MarginsCTMX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. CTMX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CTMX is creating some value.
  • CTMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CTMX Yearly Shares OutstandingCTMX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CTMX Yearly Total Debt VS Total AssetsCTMX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 4.78 indicates that CTMX is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.78, CTMX is in the better half of the industry, outperforming 73.17% of the companies in the same industry.
  • CTMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.78
ROIC/WACC1.77
WACC8.84%
CTMX Yearly LT Debt VS Equity VS FCFCTMX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

  • CTMX has a Current Ratio of 3.64. This indicates that CTMX is financially healthy and has no problem in meeting its short term obligations.
  • CTMX has a Current ratio of 3.64. This is comparable to the rest of the industry: CTMX outperforms 43.63% of its industry peers.
  • CTMX has a Quick Ratio of 3.64. This indicates that CTMX is financially healthy and has no problem in meeting its short term obligations.
  • CTMX's Quick ratio of 3.64 is in line compared to the rest of the industry. CTMX outperforms 46.14% of its industry peers.
Industry RankSector Rank
Current Ratio 3.64
Quick Ratio 3.64
CTMX Yearly Current Assets VS Current LiabilitesCTMX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CTMX Growth Analysis

3.1 Past

  • CTMX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -110.51%.
EPS 1Y (TTM)-110.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-195.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-98.27%

3.2 Future

  • Based on estimates for the next years, CTMX will show a very strong growth in Earnings Per Share. The EPS will grow by 27.49% on average per year.
  • The Revenue is expected to grow by 22.32% on average over the next years. This is a very strong growth
EPS Next Y-854.5%
EPS Next 2Y-205.73%
EPS Next 3Y-93.23%
EPS Next 5Y27.49%
Revenue Next Year-68.3%
Revenue Next 2Y-36.49%
Revenue Next 3Y-11.6%
Revenue Next 5Y22.32%

3.3 Evolution

CTMX Yearly Revenue VS EstimatesCTMX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
CTMX Yearly EPS VS EstimatesCTMX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. CTMX Valuation Analysis

4.1 Price/Earnings Ratio

  • CTMX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CTMX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTMX Price Earnings VS Forward Price EarningsCTMX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CTMX is valued cheaply inside the industry as 93.24% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 20.08
CTMX Per share dataCTMX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

  • A cheap valuation may be justified as CTMX's earnings are expected to decrease with -93.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-205.73%
EPS Next 3Y-93.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CTMX Dividend Analysis

5.1 Amount

  • No dividends for CTMX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CTMX Fundamentals: All Metrics, Ratios and Statistics

CYTOMX THERAPEUTICS INC

NASDAQ:CTMX (3/18/2026, 9:59:02 PM)

Premarket: 4.5 +0.1 (+2.27%)

4.4

-1.05 (-19.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-16
Earnings (Next)05-11
Inst Owners84.82%
Inst Owner Change3.91%
Ins Owners0.8%
Ins Owner Change8.88%
Market Cap745.54M
Revenue(TTM)N/A
Net Income(TTM)28.02M
Analysts85.33
Price Target9.44 (114.55%)
Short Float %12.19%
Short Ratio6.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.22%
Min EPS beat(2)-74.27%
Max EPS beat(2)98.72%
EPS beat(4)3
Avg EPS beat(4)88.28%
Min EPS beat(4)-74.27%
Max EPS beat(4)215.22%
EPS beat(8)7
Avg EPS beat(8)121.73%
EPS beat(12)10
Avg EPS beat(12)96.64%
EPS beat(16)11
Avg EPS beat(16)69.24%
Revenue beat(2)1
Avg Revenue beat(2)-12.98%
Min Revenue beat(2)-49.71%
Max Revenue beat(2)23.76%
Revenue beat(4)3
Avg Revenue beat(4)32.06%
Min Revenue beat(4)-49.71%
Max Revenue beat(4)92.34%
Revenue beat(8)7
Avg Revenue beat(8)44.02%
Revenue beat(12)10
Avg Revenue beat(12)36.04%
Revenue beat(16)10
Avg Revenue beat(16)9.74%
PT rev (1m)8.82%
PT rev (3m)30.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-43.27%
EPS NY rev (1m)-15.2%
EPS NY rev (3m)-100%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.56
P/FCF N/A
P/OCF N/A
P/B 6.94
P/tB 7.04
EV/EBITDA 20.08
EPS(TTM)-0.04
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.67
BVpS0.63
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 17.7%
ROE 26.09%
ROCE 19.83%
ROIC 15.67%
ROICexc N/A
ROICexgc N/A
OM 20.46%
PM (TTM) 24.66%
GM N/A
FCFM N/A
ROA(3y)-3.97%
ROA(5y)-11.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 7.74%
Cap/Sales 0.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.64
Quick Ratio 3.64
Altman-Z 4.78
F-Score5
WACC8.84%
ROIC/WACC1.77
Cap/Depr(3y)42.33%
Cap/Depr(5y)55.65%
Cap/Sales(3y)1.42%
Cap/Sales(5y)2.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-110.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-195.65%
EPS Next Y-854.5%
EPS Next 2Y-205.73%
EPS Next 3Y-93.23%
EPS Next 5Y27.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-98.27%
Revenue Next Year-68.3%
Revenue Next 2Y-36.49%
Revenue Next 3Y-11.6%
Revenue Next 5Y22.32%
EBIT growth 1Y246.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.27%
EBIT Next 3Y-97.65%
EBIT Next 5YN/A
FCF growth 1Y-99.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-103.53%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOMX THERAPEUTICS INC / CTMX Fundamental Analysis FAQ

What is the fundamental rating for CTMX stock?

ChartMill assigns a fundamental rating of 4 / 10 to CTMX.


What is the valuation status for CTMX stock?

ChartMill assigns a valuation rating of 1 / 10 to CYTOMX THERAPEUTICS INC (CTMX). This can be considered as Overvalued.


What is the profitability of CTMX stock?

CYTOMX THERAPEUTICS INC (CTMX) has a profitability rating of 4 / 10.


What is the financial health of CYTOMX THERAPEUTICS INC (CTMX) stock?

The financial health rating of CYTOMX THERAPEUTICS INC (CTMX) is 7 / 10.


What is the expected EPS growth for CYTOMX THERAPEUTICS INC (CTMX) stock?

The Earnings per Share (EPS) of CYTOMX THERAPEUTICS INC (CTMX) is expected to decline by -854.5% in the next year.